jlara

About Juan Lara

This author has not yet filled in any details.
So far Juan Lara has created 19 blog entries.

Measuring time to market for new medicines in 7 Asian countries between 2016-21, following review by US FDA or EMA

During the DIA Global Annual Meeting 2023, Adem Kermad, Magda Bujar and Neil McAuslane developed and presented a poster in which they shared the results, recommendations and conclusions about [...]

2024-04-12T09:04:51+00:00August 15th, 2023|Tags: , |

Evaluation of the Effectiveness and Efficiency of Ten Years’ Experience with the East Africa Community Joint Assessment

During the DIA Global Annual Meeting 2023, Nancy Yang-Ngum developed and presented a poster in which she shared the results, recommendations and conclusions about the topic "Evaluation of the [...]

2024-10-30T16:55:48+00:00August 15th, 2023|Tags: , |

Evaluation of the Regulatory Review Process of the FDA Ghana: Challenges and Opportunities for Improvement

During the DIA Global Annual Meeting 2023, Mercy Owusu-Asante developed and presented a poster in which she shared the results, recommendations and conclusions about the topic "Evaluation of the [...]

2023-08-15T23:27:14+00:00August 15th, 2023|Tags: , |

Evaluation of the impact of reliance on the regulatory performance in the South African Health Products Regulatory Authority

During the DIA Global Annual Meeting 2023, Lorraine Danks, Boitumelo Semete-Makokotlela, Sam Salek and Stuart Walker developed and presented a poster in which they shared the results, recommendations and [...]

2023-08-15T23:22:57+00:00August 15th, 2023|Tags: , , , |

A comparison of the Regional Medicines Regulatory Harmonisation Projects in East, West and Southern Africa.

During the DIA Global Annual Meeting 2023, Tariro Sithole, Nancy Ngum, Mercy Owusu-Asante, Stuart Walker and Sam Salek developed and presented a poster in which they shared the results, [...]

2024-10-30T16:56:51+00:00August 15th, 2023|Tags: , |

CIRS RD Briefing 88 – New drug approvals in six major authorities 2013-2022: Focus on orphan designation and facilitated regulatory pathways

This R&D Briefing presents the results from the Centre for Innovation in Regulatory Science (CIRS) annual analysis of new active substance (NAS) approvals by six major regulatory agencies: the [...]

CIRS RD Briefing 87 – A Roadmap for Regulatory Strengthening: CIRS Tools for Measuring and Optimising Regulatory Performance to Support Practices in Line with the World Health Organization Global Benchmarking Tool Indicators

Over the last 20 years, CIRS has been developing regulatory science tools to increase transparency of processes, support quality regulatory decision making, and provide global advocacy in support of [...]

2024-04-12T09:05:02+00:00June 13th, 2023|Tags: , |
Go to Top